All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-01-12T15:23:16.000Z

Why are novel TKIs needed for Ph+ ALL? What does this mean for patients?

By Camilla Rossi
Featured
Jorge Cortes
Jan 12, 2022
Share:

Bookmark this article

During the 63rd ASH Annual Meeting and Exposition, the ALL Hub was pleased to speak with Jorge Cortes, Augusta University, Augusta, US. We asked, Why are novel TKIs needed for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)? What does this mean for patients?

Why are novel TKIs needed for Ph+ ALL? What does this mean for patients?

Cortes begins by explaining that despite a dramatic evolution in treatment, risks and outcomes for many patients can still improve. Cortes highlights hopes for better quality of life, higher cure rate, fewer toxicities, and reduced need for stem cell transplants. Finally, he discusses prospects for patients with Ph+ ALL.

 

More about...
ASH 2021Philadelphia chromosome-positive / BCR-ABL1Tyrosine kinase inhibitors

Related articles

Add bookmark

Frontline treatments for older patients with Ph− B-ALL

Acute lymphoblastic leukemia (ALL) represents 5% of all newly diagnosed leukemias in older patients aged 55 to 70 years old. With recent advances largely centered around the younger population,...

Jan 20, 2022
Add bookmark

Frontline treatments for older patients with Ph− B-ALL

Acute lymphoblastic leukemia (ALL) represents 5% of all newly diagnosed leukemias in older patients aged 55 to 70 years old. With recent advances...

Jan 20, 2022
Add bookmark

Is TKI therapy effective in patients with ABL-class fusion ALL?

During the 25th Congress of the European Hematology Association (EHA), the ALL Hub spoke to Anthony Moorman, Newcastle University, Newcastle upon Tyne, UK. We asked, Is TKI therapy...

Jun 29, 2020
Add bookmark

Is TKI therapy effective in patients with ABL-class fusion ALL?

During the 25th Congress of the European Hematology Association (EHA), the ALL Hub spoke to Anthony Moorman, Newcastle University,...

Jun 29, 2020

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox